Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + vinorelbine + pembrolizumab as second-line therapy before autologous stem cell transplantation in relapsed or refractory classical Hodgkin lymphoma
IRCT20240622062212N2Phase 2Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, vinorelbine and pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Iran University of Medical Sciences. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on IRCT20240622062212N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240622062212N2.